Current pharmacological approaches to the therapy of varicella zoster virus infections. A guide to treatment

Drugs

Volumn 57, Issue 2, 1999, Pages 187-206

  Snoeck, Robert ^a   Andrei, Graciela ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; DNA POLYMERASE; FAMCICLOVIR; FIACITABINE; FIALURIDINE; FOSCARNET; LOBUCAVIR; NETIVUDINE; OXETANOCIN; PENCICLOVIR; SORIVUDINE; THYMIDINE KINASE; VALACICLOVIR; VARICELLA ZOSTER VACCINE; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANCER; CHICKENPOX; CROSS RESISTANCE; DISEASE COURSE; DNA SYNTHESIS INHIBITION; DRUG BIOAVAILABILITY; DRUG RESISTANCE; ENZYME INHIBITION; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PHOSPHORYLATION; POSTHERPETIC NEURALGIA; PREGNANCY; PREMATURITY; VACCINATION;

ANTIVIRAL AGENTS; CHICKENPOX; DRUG RESISTANCE, MICROBIAL; HERPES ZOSTER; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; VIRAL VACCINES;

EID: 0033009207     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957020-00005     Document Type: Article

References (230)

1. Weller TH. Varicella and herpes zoster: changing concepts of the natural history, control, and importance of a not-so-benign virus (2 Pt 1). N Engl J Med 1983; 309: 1362-8
2. Weller TH. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus (2 Pt 2). N Engl J Med 1983; 309: 1434-40
3. Gilden DH, Mahalingam R, Dueland AN, et al. Herpes zoster: pathogenesis and latency. In: Melnick JL, editor. Progress in Medical Virology. Vol. 39. Karger: Basel, 1992: 19-75
4. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996; 9: 361-81
5. Weber DM, Pellechia JA. Varicella pneumonia. JAMA 1965; 192: 572-3
6. Wallace MR, Bowler WA, Murray NB, et al. Treatment of adult varicella with oral acyclovir: a randomized, placebo-controlled trial. Ann Intern Med 1992; 117: 358-63
7. Hockberger RS, Rothstein RJ. Varicella pneumonia in adults: a spectrum of disease. Ann Emerg Med 1986; 15: 931-4
8. Triebwasser JH, Harris RE, Bryant RE, et al. Varicella pneumonia in adults. Medicine 1967; 46: 409-21
9. Nikkels AF, Delvenne P, Sadzot-Delvaux C, et al. Distribution of varicella zoster virus and herpes simplex virus in disseminated fatal infections. J Clin Pathol 1996; 49: 243-8
10. Haake DA, Zakowski PC, Haake DL, et al. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis 1990; 12: 788-97
11. Lotshaw RR, Keegan JM, Gordon HR. Parenteral and oral acyclovir for management of varicella pneumonia in pregnancy: a case report with review of literature. W V Med J 1991; 87: 204-6
12. Smego Jr RA, Asperilla MO. Use of acyclovir lor varicella pneumonia during pregnancy. Obstet Gynecol 1991; 78: 1112-6
13. Clements DA, Katz SL. Varicella in a susceptible pregnant woman. In: Remington JS, Swartz MN, editors. Current clinical topics in infectious diseases. Boston (MA): Blackwell Scientific Publications, 1993: 123-30
14. Pratt RD, Bradley JS, Loubert C, et al. Rhabdomyolysis associated with acute varicella infection. Clin Infect Dis 1995; 20: 450-3
15. Enders G, Miller E, Cradock-Watson J, et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343: 1548-51
16. Katz VL, Kuller JA, McMahon MJ, et al. Varicella during pregnancy: maternal and fetal effects. J Med 1995; 163: 446-50
17. Paryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 1986; 314: 1542-6
18. Gershon A. Chickenpox, measles, and mumps. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. 3rd ed. Philadelphia (PA): WB Saunders, 1990: 395-445
19. Gershon AA. Varicella-zoster virus: prospects for control. Adv Pediatr Infect Dis 1995; 10: 93-124
20. Brunell PA. Varicella in pregnancy, the fetus, and the newborn: problems in management. J Infect Dis 1992; 166 Suppl 1: S42-7
21. Brunell PA. Fetal and neonatal varicella-foster infections. Semin Perinatal 1983; 7: 47-56
22. Elliott KJ. Other neurological complications of herpes zoster and their management. Ann Neurol 1994; 35 Suppl: S57-61
23. Schimpff S, Serpick A, Stoler B, et al. Varicella-zoster infection in patients with cancer. Ann Intern Med 1972; 76: 241-54
24. Goffinet DR, Glatstein EJ, Merigan TC. Herpes zoster-varicella infections and lymphoma. Ann Intern Med 1972; 76: 235-40
25. Mazur MH, Dolin R. Herpes zoster at the NIH: a 20-year experience. Am J Med 1978; 65: 738-44
26. Taylor CE, Sviland L, Pearson ADJ, et al. Virus infections in bone marrow transplant recipients: a three-year prospective study. J Clin Pathol 1990; 43: 633-7
27. Meyers JD. Infection in recipients of bone marrow transplants. In: Remington JS, Schwartz MN, editors. Current clinical topics in infectious diseases. New York: McGraw-Hill Book Co., 1985: 261-92
28. Christiansen NP, Haake RJ, Hurd DD. Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant. Bone Marrow Transplant 1991; 7: 435-7
29. Tappero JW, Perkins BA, Wenger JD, et al. Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Clin Microbiol Rev 1995; 8: 440-50
30. Cockerell CJ. Human immunodeficiency virus infection and the skin: a crucial interface. Arch Intern Med 1991; 151: 1295-303
31. Cohen PR, Beltrani VP, Grossman ME. Disseminated herpes zoster in patients with human immunodeficiency virus infection. JAMA 1988; 84: 1076-80
32. Liebovitz E, Kaul A, Rigaud M, et al. Chronic varicella zoster in a child infected with human immunodeficiency virus: case report and review of the literature. Cutis 1992; 49: 27-31
33. Nelson JA, Ghazal P, Wiley CA. Role of opportunistic viral infections in AIDS. AIDS 1990; 4: 1-10
34. Quinnan Jr GV, Masur H, Rook AH, et al. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA 1984; 252: 72-7
35. von Siedlein L, Gillette SG, Bryson Y, et al. Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunodeficiency virus type 1. J Pediatr 1996; 128: 52-7
36. Weksler ME. Immune senescence. Ann Neurol 1994; 35 Suppl.: S35-7
37. McPherson RE. Herpes zoster opthalmicus and the immunocompromised host: a case report and reviews. J Am Optom Assoc 1997; 68: 527-38
38. Jemsek J, Greenberg SB, Taber L, et al. Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine 1983; 62: 81-97
39. Straus SE, Ostrove JM, Inchausp G, et al. Varicella-zoster virus infections: biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108: 221-37
40. Griffin DE. Therapy of viral infections of the central nervous system. Antiviral Res 1991; 15: 1-10
41. Gelb LD. Varicella-zoster virus. In: Fields BN, Knipe DM, editors. Virology. New York: Raven Press, 1990: 2011-54
42. Ryder JW, Croen K, Kleinschmidt-DeMasters BK, et al. Progressive encephalitis three months after resolution of cutaneous zoster in a patient with AIDS. Ann Neurol 1986; 19: 182-8
43. Dueland AN, Devlin M, Martin JR, et al. Fatal varicella-zoster virus meningoradiculitis without skin involvement. Ann Neurol 1991; 29: 569-72
44. Gilden DH, Dueland AN, Devlin ME, et al. Varicella-zoster virus reactivation without rash. J Infect Dis 1992; 166 Suppl. 1: S30-4
45. Heller HM, Carnevale NT, Steigbigel RT. Varicella zoster virus transverse myelitis without cutaneous rash. Am J Med 1990; 88: 550-1
46. Snoeck R, Gérard M, Sadzot-Delvaux C, et al. Meningoradiculoneuritis due to acyclovir-resistant varicella-zoster virus in an AIDS patient. J Med Virol 1994; 42: 338-47
47. Mouligner A, Pialoux G, Dega H, et al. Brain stem encephalitis due to varicella-zoster virus in a patient with AIDS. 1995. Clin Infect Dis 20: 1378-80
48. Poscher ME. Successful treatment of varicella zoster virus meningoencephalitis in patients with AIDS: report of four cases and review. AIDS 1994; 8: 1115-7
49. de Silva SM, Mark AS, Gilden DH, et al. Zoster myelitis: improvement with antiviral therapy in two cases. Neurology 1996; 47: 929-31
50. Lionnet F, Pulik M, Genet P, et al. Myelitis due to varicella-zoster virus in two patients with AIDS: successful treatment with acyclovir. Clin Infect Dis 1996; 22: 138-40
51. Gilden DH, Beinlich BR, Rubinstein EM, et al. Varicella-zoster virus myelitis: an expanding spectrum. Neurology 1994; 44: 1818-23
52. Batisse M, Eliaszewicz M, Zazoun L, et al. Acute retinal necrosis in the course of AIDS: study of 26 cases. AIDS 1996; 10: 55-60
53. Figueroa MS, Garabito I, Gutierrez C, et al. Famciclovir for the treatment of acute retinal necrosis (ARN) syndrome. Am J Ophthalmol 1997; 123: 255-7
54. Arvin AM. Varicella-zoster virus. In: Fields BN, Knipe DM, Howley PM, et al., editors. Field's virology. 3rd ed. Philadelphia (PA): Lippincott-Raven, 1996: 2547-85
55. Brunell PA, Ross A, Miller LH, et al. Prevention of varicella by zoster immune globulin. N Engl J Med 1969; 280: 1191-4
56. Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin: a further assessment. N Engl J Med 1974; 290: 243-5
57. Centers for Disease Control. Varicella zoster immune globulin for the prevention of chickenpox: recommendations of the immunizations practices advisory committee. Ann Intern Med 1984; 100: 859-65
58. Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983; 147: 737-43
59. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996; 45: 1-36
60. Gershon AA. Varicella vaccine: its past, present and future. Pediatr Infect Dis J 1995; 14: 742-4
61. Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; II: 1288-90
62. Feldman S, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics 1987; 80: 465-72
63. Hardy IB, Gershon A, Steinberg S, et al. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med 1991; 325: 1545-50
64. Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9: 642-7
65. Asano Y, Nagai T, Miyata T. et al. Long-term protective immunity of recipients of the Oka strain of live varicella vaccine. Pediatrics 1985; 75: 667-71
66. Hayward A, Villanueba E, Cosyns M, et al. Varicella-zoster virus (VZV)-specific cytotoxicity after immunization of nonimmmune adults with Oka strain attenuated VZV vaccine. J Infect Dis 1992; 166: 260-4
67. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992; 11: 19-23
68. Diaz PS, Au D, Smith S, et al. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991; 87: 166-70
69. Gershon AA. Human immune responses to live attenuated varicella vaccine. Rev Infect Dis 1991; 13, Suppl 11: S957-9
70. Gershon AA. Steinberg S, NIAID Collaborate Varicella Vaccine Study Group. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989; 320: 892-7
71. Tsolia M, Gershon A, Steinberg S, et al. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J Pediatr 1990; 116: 184-9
72. Brunell PA, Taylor-Wiedeman J, Geiser CF, et al. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 1986; 77: 53-6
73. Berger R, Luescher D, Just M. Enhancement of varicella-zoster-specific immune response in the elderly by boosting with varicella vaccine [letter]. J Infect Ois 1984; 149: 647
74. Hayward A, Levin M, Wolf W, et al. Varicella-zoster virus-specific immunity after herpes zoster. J Infect Dis 1991; 163: 873-5
75. Takahashi M, Iketani T, Sasada K, et al. Immunization of the elderly and patients with collagen vascular diseases with live varicella vaccine and use of varicella skin antigen. J Infect Dis 1992; 166 Suppl. 1: S58-62
76. Sperber SJ, Smith BV, Hayden FG. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. Antiviral Res 1992; 17: 213-22
77. Lawrence R, Gershon A, Holzman R, et al. The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med 1988; 318: 543-8
78. Gershon AA, LaRussa P, Hardy I, et al. Varicella vaccine: the American experience. J Infect Dis 1992; 166 Suppl. 1: S63-8
79. Levin MJ, Murray M, Rotbart HA. et al. Immune response of elderly individuals to a live-attenuated varicella vaccine. J Infect Dis 1992; 166: 258-9
80. Levin MJ, Murray M, Zerbe CO, et al. Immune responses of elderly persons 4 years after receiving a live-attenuated vaccine. J Infect Dis 1994; 170: 522-6
81. Committee on Infectious Diseases. Recommendations for the use of live attenuated varicella vaccines. Pediatrics 1995; 95: 791-6
82. ACG Task Force on Adult Immunization and Infectious Disease Society of America. Guide for adult immunisation. 3rd ed. Philadelphia (PA): American College of Physicians, 1994
83. Lin TY, Huang YC, Ning HC, et al. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997; 16: 1162-5
84. Yoshikawa T, Suga S, Kozawa T, et al. Persistence of protective immunity after postexposure prophylaxis of varicella with oral aciclovir in the family setting. Arch Dis Child 1998; 78: 61-3
85. Easterbrook P, Wood MJ. Successors to acyclovir. J Antimicrob Chemother 1994; 34: 307-11
86. Cunningham AL, Dwyer DE. Advances and controversies in the antiviral therapy of herpes zoster. Eur J Clin Microbiol Infect Dis 1996; 15: 273-5
87. Alrabiah FA, Sacks SL. New antiherpesvirus agents: their targets and therapeutic potential. Drugs 1996; 52: 17-32
88. Nikkels AF, Piérard GE. Recognition and treatment of shingles. Drugs 1994; 48: 528-48
89. Wagstaff AJ, Faulds D, Goa KL. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetics properties and therapeutic efficacy. Drugs 1994; 47: 153-205
90. Perry CM, Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996; 52: 754-72
91. Perry CM, Wagstaff AJ. Famciclovir: a review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995; 50: 398-415
92. Balfour Jr HH, Kelly JM, Suarez CS, et al. Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 1990; 116: 633-9
93. Dunkle LM, Arvin AM, Wnitley RJ, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991; 325: 1539-44
94. Baltour Jr HH, Dunkle LM, Feder HM, et al. Acyclovir treatment of varicella in otherwise healthy adolescents. J Pediatr 1993; 120: 627-33
95. Al-Nakib W, Al-Kandari S, El-Khalik DM, et al. A randomized controlled study of intravenous acyclovir (Zovirax) against placebo in adults with chickenpox. J Infect 1983; 6: 49-56
96. Feder HM. Treatment of adult chickenpox with oral acyclovir. Arch Intern Med 1990; 150: 2061-5
97. Rothe MJ, Feder Jr HM, Grant-Kels JM. Oral acyclovir therapy for varicella and zoster infections in pediatric and pregnant patients: a brief review. Pediatr Dermatol 1991; 8: 236-42
98. Committee on Infectious Diseases. The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics 1993; 91: 674-6
99. Wallace MR, Chamberlin CJ, Sawyer MM, et al. Treatment of adult varicella with sorivudine: a randomized, placebo-controlled trial. J Infect Dis 1996; 174: 249-55
100. Whitley RJ. Sorivutline: a potent inhibitor of varicella zoster virus replication. Adv Exp Med Biol 1996; 394: 41-4
101. Stevens DA, Jordan GW, Waddall TP, et al. Adverse effects of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med 1973; 289: 873-8
102. Chow AW, Forester JH, Hryniuk W. Cytosine arabinoside therapy for herpesvirus infections. Antimicrob Agents Chemother 1970; 10: 214-7
103. Whitley RJ, Gnann Jr JW. Acyclovir: a decade later. N Engl J Med 1992; 327: 782-9
104. Arvin A, Feldman S, Merigan TC. Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial. Antimicrob Agents Chemother 1978; 13: 605-7
105. Arvin AM, Kushner JH, Feldman S, et al. Human leukocyte interferon for treatment of varicella in children with cancer. N Engl J Med 1982; 306: 761-5
106. Whitley RJ, Hilty M, Haynes R, et al. Vidarabine therapy of varicella in immunosuppressed patients. J Pediatr 1982; 1: 125-31
107. Prober DG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children - a collaborative study. J Pediatr 1982; 101: 622-5
108. Nyerges G, Meszner Z, Gyarmati E, et al. Acyclovir prevents dissemination of varicella in immunocompromised children. J Infect Dis 1988; 157: 309-13
109. Meszner Z, Nyerges G, Bell AR. Oral acyclovir to prevent dissemination of varicella in immunocompromised children. J Infect 1993; 26: 9-15
110. Bean B, Braun C, Balfour Jr HH. Acyclovir therapy for acute herpes zoster. Lancet 1982; II: 118-21
111. Peterslund NA, Seyer-Hansen K, Ipen J, et al. Acyclovir in herpes zoster. Lancet 1981; II: 827-30
112. McGill J, MacDonald DR, Fall C, et al. Intravenous acyclovir in acute herpes zoster infection. J Infect Dis 1983; 6: 157-61
113. Wood MJ, Ogan PH, McKendrick MW, et al. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988; 85 Suppl. 2A: 79-83
114. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102: 93-5
115. Cobo LM, Foulks GN, Liesegang T. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986; 93: 763-70
116. McGill J, Chapman C. A comparison of topical acyclovir with steroids in the treatment of herpes zoster keratouveitis. Br J Ophthalmol 1983; 67: 746-50
117. Mondelli M, Romano C, Passero S, et al. Effects of acyclovir on sensory axonal neuropathy, segmental motor paresis and postherpetic neuralgia in herpes zoster patients. Eur Neurol 1996; 36: 288-92
118. Bowsher D. The management of postherpetic neuralgia. Postgrad Med J 1997; 73: 623-9
119. Eaglstein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 1970; 211: 1681-3
120. Elliott FA. Treatment of herpes zoster with high doses of prednisone. Lancet 1964; 11: 610-1
121. Esmann V, Kroon S, Peterslund NA. Prednisolone does not prevent postherpetic neuralgia. Lancet 1987; 11: 126-9
122. Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes roster. N Engl J Med 1994; 330: 896-900
123. Whitley RJ, Weiss H, Gnann JR JW, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. Ann Intern Med 1996; 125: 376-83
124. Huff JC, Drucker JL, Clemmer A, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993; Suppl. 1: 93-6
125. Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157: 1217-24
126. Jackson JL, Gibbons R, Meyer G, et al. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis. Arch Intern Med 1997; 157: 909-12
127. Beutner KR, Friedman DJ, Porszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39: 1546-53
128. Herne K, Cirelli R, Lee P, et al. Antiviral therapy of acute herpes zoster in older patients. Drugs Aging 1996; 8: 97-112
129. Duschet P, Auer-Grumbach P, Gschnait F. Efficacy and safety of penciclovir (PCV) in the treatment of patients with herpes zoster (HZ): a double-blind, randomised, acyclovir (ACV)-controlled study [abstract no. 1708], Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992 Oct 11-14; Anaheim (CA)
130. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 89-96
131. Huse DM, Schainbaum S, Kirsch AJ, et al. Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. Am J Health Syst Pharm 1997; 54: 1180-4
132. Degreef H, Famciclovir herpes zoster clinical study group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994; 4: 241-6
133. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994; 38: 2454-7
134. Merigan TC, Rand KH, Pollard RB. Human leukocyte Interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med 1978; 298: 981-7
135. Whitley RJ, Ch'ien I.T, Dolin R, et al. Adenine arabinoside therapy of herpes zoster in the immunosuppressed. N Engl J Med 1976; 294: 1193-9
136. Whitley RJ, Soong SJ, Dolin R, et al. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med 1982; 307: 971-5
137. Johnson MT, Luby JP, Buchanan RA, et al. Trealment of varicella-zoster virus infections with adenine arabinoside. J Infect Dis 1975; 131: 225-9
138. Biron KK, Elion GB. In vitro susceptibility of varicella-zoster to acyclovir. Antimicrob Agents Chemother 1980; 18: 443-7
139. Balfour Jr HH, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308: 1448-53
140. Shepp D, Dandliker PS, Meyers JD. Treatment of varicella-zoster virus in severely immunocompromised patients: a randomized comparison of acyclovir and vidarabine. N Engl J Med 1986; 314: 208-12
141. Whitley RJ. Therapeutic approaches to varicella-zoster virus infections. J Infect Dis 1992; 166 Suppl. 1: S51-7
142. Whitley RJ, Gnann Jr JW, Hinthorn D, et al. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. J Infect Dis 1992; 165: 450-5
143. Dullaert H, Maudgal PC, Leys A, et al. Bromovinyldeoxyuridine treatment of outer retinal necrosis due to varicella-zoster virus: a case report. Bull Soc Belge Ophtalmol 1997; 262: 107-13
144. Wutzler P, De Clercq E, Wutke K, et al. Oral brivudin vs intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 1995; 46: 252-7
145. Wildiers J, De Clercq E. Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine treatment of severe herpes zoster in cancer patients. Eur J Cancer Clin Oncol 1984; 4: 471-6
146. Benoit Y, Laureys G, Delbeke M-J, et al. Oral BVDU treatment of varicella and zoster in children with cancer. Eur J Pediatr 1985; 143: 198-202
147. Maudgal PC, Dralands L, Lamberts L, et al. Preliminary results of oral BVDU treatment of herpes zoster ophthalmicus. Bull Soc Belge Ophthal 1981; 193: 49-56
148. De Clercq E, Degreef H, Wildiers J, et al. Oral (E)-5-(2-Bromovinyl)-2′-deoxyuridine in severe herpes zoster [letter]. BMJ 1980; 281: 1178
149. Niimura M. A double-blind clinical study in patients with herpes zoster to establish YN-72 (Brovavir) dose. Adv Exp Med Biol 1990; 278: 267-75
150. Niimura M, Nishikawa T, Ogawa H, et al. YN-72 dose-finding double-blind clinical study in patients with herpes zoster: the study of clinical efficacy. Clin Virol 1990; 18: 115-26
151. Hiraoka A, Masaoka T, Nagai K, et al. Clinical effect of BV-araU on varicella-zoster virus infection in immunocompromised patients with haematological malignancies. J Antimicrob Chemother 1991; 27: 361-7
152. Gnann JR JW, Crumpacker CS, Lalezari JP, et al. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Antimicrob Agents Chemother 1998; 42: 1139-45
153. Desgranges C, Razaka G, De Clercq E, et al. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 1986; 46: 1094-101
154. Okuda H, Nishiyama T, Ogura K, et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 1997; 25: 270-3
155. Pahwa S, Biron K, Lim W, et al. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 1988; 260: 2879-82
156. Linnemann Jr CC, Biron KK, Hoppenjans WG, et al. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS 1990; 4: 577-9
157. Jacobson MA, Berger TG, Fikrig S, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112: 187-91
158. Smith KJ, Kahlter C, Davis C, et al. Acyclovir-resistant varicella zoster responsive to foscarnet. Arch Dermatol 1991; 127: 1069-71
159. Cole NL, Balfour Jr HH. Varicella-zoster does not become more resistant to acyclovir during therapy. J Infect Dis 1986; 153: 605-8
160. Mori H, Shiraki K, Kato T, et al. Molecular analysis of the thymidine kinase gene of thymidine kinase-deficient mutants of varicella-zoster virus. Intervirology 1988; 29: 301-10
161. Lacey SF, Suzutani T, Powell KL, et al. Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction. J Gen Virol 1991; 72: 623-30
162. Suzutani T, Lacey SF, Powell KL, et al. Random mutagenesis of the thymidine kinase gene of varicella-zoster virus. J Virol 1992; 66: 2118-24
163. Roberts GB, Fyfe JA, Gaillard RK, et al. Mutant varicclla-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment. J Virol 1991; 65: 6407-13
164. Shiroaki K, Namazue J, Okuno T, et al. Novel sensitivity of acyclovir-resistant varicella-zoster virus to anti-herpetic drugs. Antiviral Chem Chemother 1990; 1: 373-5
165. Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 1993; 67: 1024-33
166. Boivin G, Edelman CK, Pedneault L, et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994; 170: 68-75
167. Safrin S, Berger TG, Gilson I, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991; 115: 19-21
168. Lietman PS. Clinical pharmacology: foscarnet. Am J Med 1992; 92 Suppl. 2A: 85-115
169. Raffi F, Taburet AM, Ghaleh B, et al. Penetration of foscarnet into cerebrospinal fluid of AIDS patients. Antimicrob Agents Chemother 1993; 37: 1777-80
170. Hengge UR, Brockmeyer NH, Malessa R, et al, Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. Antimicrob Agents Chemother 1993; 37: 1010-4
171. Fillet A-M, Visse B, Caumes E, et al. Foscarnet-resistant multi-dermatomal zoster in a patient with AIDS. Clin Infect Dis 1995; 21: 1348-9
172. Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 1977; 74: 5716-20
173. Fyfe JA, Keller PM, Furman PA, et al. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem 1978; 253: 8721-7
174. Derse D, Cheng Y-C, Furman PA, et al. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate: effects on primer-template function. J Biol Chem 1981; 256: 11447-51
175. Furman PA, St Clair MH, Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem 1984; 259: 9575-9
176. Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase: mechanism of inhibition by acyclovir triphosphate. J Biol Chem 1989; 264: 7405-11
177. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983; 12 Suppl. B: 29-37
178. Weller S, Blum M, Doulette M, et al. Pharmacokinetics of the acyclovir prodrug, valaciclovir, after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmcol Ther 1993, 54: 595-605
179. Spiegal DM, Lau K. Acute renal failure and coma secondary to acyclovir therapy. JAMA 1986; 255: 1882-3
180. Bianchetti MG, Roduit C, Oetliker OH. Acyclovir-induccd renal failure: course and risk factors. Pediatr Nephrol 1991; 5: 238-9
181. Huff JC, Bean B, Balfour Jr HH, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988; 85 Suppl. 2A: 84-9
182. Cohen SMZ, Minkove JA, Zehley JW, et al. Severe but reversible neurotoxicity from acyclovir |letter|. Ann Intern Med 1984; 100: 920
183. Wade JC, Meyers JD. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med 1983; 98: 921-5
184. Boyd MR, Bacon TH, Sutton D, et al. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987; 31: 1238-42
185. Vere Hodge RA. Famciclovir and penciclovir: the mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 1993; 4: 67-84
186. Vere Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 1989; 33: 223-9
187. Earnshaw DL, Bacon TH, Darlison SJ, et al. Penciclovir: mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992; 36: 2747-57
188. 188. Boyd MR, Bacon TH, Sutton D. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethy]but-1-yl)guanine (BRL 39123) in animals. Antimicrob Agents Chemother 1988; 32: 358-63
189. Vere Hodge RA, Sutton D, Boyd MR, et al. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989; 33: 1765-73
190. Winton CF, Fowles SE, Vere Hodge RA, et al. Assay of famciclovir and its metabolites, including the antiherpes agent penciclovir, in plasma and urine of rat, dog and man. In: Reid E, Wilson ID, editors. Analysis of drugs and metabolites. Cambridge: Royal Society of Chemists, 1990: 163-71
191. Littler E, Ertl P, Emmerson A, et al. Comparative anti-viral effects of acyclovir and penciclovir (famciclovir) [abstract no. 14]. Antiviral Res 1993; Suppl. 1: 53
192. Crumpacker C. The pharmacological profile of famciclovir. Semin Dermatol 1996; 15 Suppl. 1: 14-26
193. Sakuma T. Strains of varicella-zoster virus resistant to 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Antimicrob Agents Chemother 1984; 25: 742-6
194. Yokota T, Konno K, Shigeta S, et al. Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2′-deoxyuridine 5′-triphosphate. Mol Pharmacol 1984; 26: 376-80
195. Machida H, Ijichi K, Ohta A, et al. Antiviral potencies of BV-araU and related nucleoside analogues against varicella-zoster virus in different cell lines. Microbiol Immunol 1990; 34: 959-65
196. Soike KF, Cantrell C, Gerone PJ. Activity of 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodouracil against simian varicella virus infections in African green monkeys. Antimicrob Agents Chemother 1986; 29: 20-5
197. Soike KF, Gibson S, Gerone PJ. Inhibition of simian varicella virus infection of African green monkeys by (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU). Antiviral Res 1981; 1: 325-37
198. Leyland-Jones B, Donnelly H, Groshen S, et al. 2′-Fluoro-5-iodoarabinosylcytosine, a new potent antiviral agent: efficacy in immunosuppressed individuals with herpes zoster. J Infect Dis 1986; 154: 430-6
199. Rahim SG, Trivedi N, Pether MJ, et al. 5-Alkynyl pyrimidine nucleosides as potent selective inhibitors of varicella zoster virus (VZV) [abstract no. 179]. Antiviral Res 1993; 20 Suppl. 1: 139
200. Talarico CL, Stanat SC, Rahim SG, et al. In vitro antiviral activity of 1 -(beta-D-arabinofuranosyl)-5-(1 -propynyl)uracil against varicella zoster virus [abstract no. 128]. Antiviral Res 1993; Suppl. 1: 113
201. Fillastre JP, Godin M, Legallicier B, et al. Pharmacokinetics of netivudine, a potent anti-varicella zoster virus drug, in patients with renal impairment. J Antimicrob Chemother 1996; 37: 965-74
202. Peck RW, Wootton R, Lee DR, et al. The bioavailability and disposition of 1 -(β-D-arabinofuranosyl)-5-(1 -propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent. Br J Clin Pharmacol 1995; 39: 143-9
203. Wood MJ, McKendrick MW, Mandal B, et al. An open study of 882C to investigate clinical potential, pharmacokinetics and safety in patients with herpes zoster [abstract no. P26-6]. Abstracts of the Ninth International Congress of Virology; 1993 Aug 8-13; Glasgow, 204
204. Averett DR, Koszalka GW, Fyfe JA, et al. 6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus. Antimicrob Agents Chemother 1991; 35: 851-7
205. Myers MG, Stanberry LR. Drug testing for activity against varicella-zoster virus in hairless guinea pigs. Antiviral Res 1991; 15: 341-4
206. Koszalka GW, Averett DR, Fyfe JA et al. 6-N-Substituted derivatives of adenine arabinoside as selective inhibitors of varicella-zoster virus. Antimicrob Agents Chemother 1991; 35: 1437-43
207. Sakuma T, Saijo M, Suzutani T, et al. Antiviral activity of oxetanocins against varicella-zoster virus. Antimicrob Agents Chemother 1991; 35: 1512-4
208. Alder J, Mitten M, Norbeck D, et al. Efficacy of A-73209, a potent orally active agent against VZV and HSV infections. Antiviral Res 1994; 23: 93-105
209. Yokota T, Konno K, Shigeta S. Inhibition of thymidylate synthetase activity induced in varicella-zoster virus infected cells by (E)-5-(2-bromovinyl)-2′-deoxyuridine [abstract 135]. Antiviral Res 1993; 20 Suppl. 1: 117
210. Cohen JI, Seidel KE. Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. Proc Natl Acad Sci U S A 1993; 90: 7376-80
211. Spector T, Harrington JA, Morrison Jr RW, et al. 2-Acetylpyridine 5-[(dimethylamino)-thiocarbonyl]thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir. Proc Natl Acad Sci U S A 1989; 86: 1051-5
212. Spector T, Harrington JA, Porter DJT. Herpes and human ribonucleotide reductases. Biochem Pharmacol 1991; 42: 91-6
213. Chrisp P, Clissold SP. Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991; 41: 104-29
214. De Clercq E, Holy A, Rosenberg I, et al. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323: 464-7
215. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987; 8: 261-72
216. Snoeck R, Sakuma T, De Clereq E, et al. (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 1988; 32: 1839-44
217. Balzarini J, Naesens L, Herdewijn P et al. Marked in vivo anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci U S A 1989; 86: 332-6
218. Baba M, Konno K, Shigela S, et al. In vitro activity of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against newly isolated clinical varicella-zoster virus strains. Eur J Clin Microbiol 1987; 6: 158-60
219. De Clercq E. Therapeutic potential of HPMPC as an antiviral drug. Rev Med Virol 1993; 3: 85-96
220. Naesens L, Snoeck R, Andrei G, et al. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemother 1997; 8: 1-23
221. Hitchcock MJM, Jaffe HS, Martin JC, et al. Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem Chemother 1996; 7: 115-27
222. Safrin S, Cherrington J, Jaffe HS. Clinical use of cidofovir. Rev Med Virol 1997; 7: 145-56
223. Naesens L, Balzarini J, Rosenberg I, et al. 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vitro. Eur J Clin Microbiol Infect Dis 1989; 8: 1043-7
224. Snoeck R, Schols D, Sadzot-Delvaux C, et al. Flow cytometric method for the detection of gpl antigens of varicella zoster virus and evaluation of anti-VZV agents. J Virol Methods 1992; 38: 243-54
225. Neyts J, Snoeck R, Schols D, et al. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology 1990; 179: 41-50
226. Votruba I, Bernaerts R, Sakuma T, et al. Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Mol Pharmacol 1987; 32: 524-9
227. Ho H-T, Woods KL, Bronson KL, et al. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1992; 41: 197-202
228. Cihlar T, Votruba I, Horsk K, et al. Metabolism of 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cyto-sine (HPMPC) in human embryonic lung cells. Collect Czech Chem Commun 1992; 57: 661-72
229. Neyts J, Sobis H, Snoeck R, et al. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-1.1,3-dihydroxy-2-propoxymethyl)guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. Eur J Clin Microbiol Infect Dis 1993; 12: 269-79
230. Soike KF, Huang J-L, Zhang J-Y, et al. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (S-HPMPC) on simian varicella infection in monkeys. Antiviral Res 1991; 16: 17-28